Connect with Vericel’s Executive Medical Director James G. Boron, MD, FACS, FCCP at the American Burn Association Burn Surgeon Forum on Sept. 9–10 to learn about our commitment to advancing burn care therapies. The Vericel® Burn Care portfolio includes biologic therapies that provide healthcare professionals with options when assessing and treating burns. More here: https://bit.ly/3ySaNqw (For HCPs Only) #BurnCare
Vericel® Corporation’s Post
More Relevant Posts
-
Learn from a real world clinical experience to understand: - How the iTind™ procedure can fit into your BPH treatment options - Who are ideal patients for the iTind™ procedure - Who are not ideal patients for the iTind™ procedure - How to talk to patients about new technology
Wondering about the role of the iTind™ procedure in the treatment of benign prostatic hyperplasia (BPH)? Dr. Hollowell dives into the details in this on-demand #webinar. Hear more about its benefits, risks, and how it can become an option for your #BPH patients. #iTind
-
Wondering about the role of the iTind™ procedure in the treatment of benign prostatic hyperplasia (BPH)? Dr. Hollowell dives into the details in this on-demand #webinar. Hear more about its benefits, risks, and how it can become an option for your #BPH patients. #iTind
Real World Experience with iTind™ Procedure
bigmarker.com
-
Vice President of Fresenius Critical Care Sales: NxStage. NKFI Board Member. Senior Sales Leadership.
#freseniuscriticalcare #nxstagesystemone #tpe Dr. Gashti has a wealth of knowledge on Membrane TPE; please join this informative webinar
Join us for a live webinar presentation with Dr. Casey Gashti, Medical Director of Inpatient Plasmapheresis at Rush University Medical Center, on the Basics of Therapeutic Plasma Exchange (TPE). A Q&A session will follow. Register today: https://bit.ly/4bAaygV
-
-
CellerateRX® Surgical Powder has been studied in six peer-reviewed clinical publications in the last five years. Learn more about how CellerateRX Surgical can benefit your patients: https://lnkd.in/e5tdaC5
-
-
Senior commercial marketing professional, passionate about creating patient centric solutions, cascading these through storytelling - eternally focused on the "why"
I'm planning on joining Dr. Matthias Lars Grünewald on Wednesday, May 8, 2024 | 9:00am CEST | 3:00pm SGT | 5:00pm AEST in this live #ClinicalView webinar for an overview of some clinical outcomes that Surgical Pleth Index (SPI) may enable, and to hear practical tips on its usage during clinical practice. Curious? Register below 👇 #patientmonitoring
Upcoming webinar: Optimising analgesia monitoring with Surgical Pleth Index™ (SPI): What can we learn from an expert?
gehealthcare.smh.re
-
🔍 Exploring Retrograde Insertion of IVC Filter: A Crucial Bailout Plan In the realm of vascular interventions, the retrograde insertion of an Inferior Vena Cava (IVC) filter emerges as a strategic bailout plan, offering physicians a valuable tool in critical scenarios. 🚑 🔖 Read more at https://lnkd.in/dAKruxhr. 👥 Have you encountered cases where retrograde IVC filter insertion played a pivotal role? Share your experiences and insights. #VascularIntervention #IVCFilter #MedicalInnovation
-
Have you registered for our free webinar this week yet, 'PBMT for the Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy' on Wednesday 12 June 7:30pm AEST? If not, you only have one day left to join the growing number of practitioners attending to learn about the latest medical advancements in peripheral neuropathy treatment. Learning objectives: 1. Learn how PBM can be used in the management of neuropathies. 2. Discover promising clinical trials about PBM for chemotherapy-induced peripheral neuropathy (CIPN). 3. Explore optimal PBM and treatment parameters for CIPN. 4. Understand the future of research of PBM for CIPN including larger, placebo-controlled trials. Hurry, register now: https://hubs.ly/Q02xSwXj0 #mlslaser #healthcarewebinar #professionaldevelopment
-
-
US HCPs: Go endovascular first approach with #LightningBolt7! Results from Dr. de Donato reveal that 86% of patients required additional endovascular intervention post-surgical embolectomy. #CAVT Rx only. Risk info: peninc.info/risk Clinical results may vary
-
Discover clinical insights as physicians discuss the new dual-size cryoballoon catheter POLARx™ FIT. Dive into the perspectives shared by physicians in the FROzEN AF trial in this video. https://bit.ly/41UoQWK Safety info: https://bit.ly/48QAVON
-
-
US-based cardiovascular device specialist, Reflow Medical has confirmed that its stenting system, the Bare Temporary Spur Stent System, was granted the CE Mark after a clinical trial that saw the device help heal long-lasting wounds in patients suffering from conditions such as peripheral artery disease, as well as critical limb-threatening ischemia. 📢Isa R., Reflow Medical’s CEO, commented: “Earning the CE Mark is a huge milestone for the company. It enables us to offer a clinically validated solution to an unmet need in a major disease area. Our next goal is to expand our organization to commercialize this breakthrough technology and serve the needs of physicians and their patients in countries accepting this certification.” 🔗Learn more: https://lnkd.in/eTJPVJdd 📰 Follow Guided Solutionsto receive the latest #MedTech news daily and subscribe to our weekly newsletter: https://lnkd.in/ett_V9Z4 #GuidedSolutions #Cardiovascular #MedTech #MedicalDevice #CEMark #Medical
Reflow Medical granted CE mark for Spur stent system
